3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)
Recruiting · NCT05227092 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Bordeaux
View the official record on ClinicalTrials.gov →Interventions studied
3D OPTIMIZED WMN MPRAGE
What this trial is about
The aim of this study is to compare the 3D OPTIMIZED MPRAGE WMN sequence to "conventional sequences" used in spinal cord analysis. The patients will be explored at the cervical level with the conventional 2D sagittal T2 FSE, 2D sagittal STIR, 2D sagittal PSIR, 3D T1 MPRAGE sequences, and the sequence of interest 3D sagittal OPTIMIZED WMN MPRAGE and 3D axial OPTIMIZED WMN MPRAGE. At the thoracic level, with the conventional 2D sagittal T2 FSE, 2D sagittal STIR, 3D T1 MPRAGE sequences and the sequence of interest 3D sagittal OPTIMIZED WMN MPRAGE.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients older than 18 years old
- CIS or RRMS
- Medullary symptomatology less than 6 months
- With or without an objective lesion on a subsequent MRI scan
- Signed the Informed Consent
Exclusion criteria
- Pregnant or potentially pregnant women
- Breastfeeding woman
- Contraindications to MRI
- Other diagnosis (Neuro-myelitis spectrum disease or Progressive Multiple Sclerosis)
- Surgical history on the spinal cord or lumbar spine
- Patient under legal protection
Where it is running
1 location listed.
- CHU de Bordeaux - Bordeaux, France